Experts highlight the potential impact of newly developed weight loss pills, like orforglipron, on combating obesity and diabetes in low- and middle-income countries (LMICs). Current injectable drugs such as Wegovy and Mounjaro have shown effectiveness but their cost and storage requirements limit their accessibility. New oral medications, expected to be more affordable and easier to transport, could ensure broader distribution and utilization, significantly benefiting regions facing rising obesity-related health issues.
Among the drugs causing excitement is orforglipron, which comes as a daily pill for glucose control and weight loss. Like semaglutide, it opens new avenues for treatment.
Experts say new oral medications that are expected to be cheaper as well as simpler to transport and store could help tackle a growing health concern in LMICs.
Collection
[
|
...
]